{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:45:12Z","timestamp":1787003112529,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-022-00569-8","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T01:03:01Z","timestamp":1667955781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6416-8492","authenticated-orcid":false,"given":"Alessandra","family":"Buoninfante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1817-5920","authenticated-orcid":false,"given":"Arno","family":"Andeweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8232-0531","authenticated-orcid":false,"given":"Alexander T.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh","family":"Borad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Dogn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-1064","authenticated-orcid":false,"given":"David","family":"Garcia-Azorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Greinacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5734-0258","authenticated-orcid":false,"given":"Rita","family":"Helfand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Hviid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kochanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1337-7267","authenticated-orcid":false,"given":"Marta","family":"L\u00f3pez-Fauqued","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishac","family":"Nazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2519-4377","authenticated-orcid":false,"given":"Anand","family":"Padmanabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0840-5614","authenticated-orcid":false,"given":"Sue","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Prieto-Alhambra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Wandel Liminga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cavaleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"569_CR1","unstructured":"WHO. WHO Director-General\u2019s opening remarks at the media briefing on COVID-19 - 11 March 2020. https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (2020)."},{"key":"569_CR2","unstructured":"EMA. COVID-19 vaccines, Overview, European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/covid-19-vaccines (2022)."},{"key":"569_CR3","unstructured":"EMA. COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events-vaccine\u2019s benefits currently still outweigh risks-Update. https:\/\/www.ema.europa.eu\/en\/news\/covid-19-vaccine-astrazeneca-prac-investigating-cases-thromboembolic-events-vaccines-benefits (2021)."},{"key":"569_CR4","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1001\/jama.2021.7517","volume":"325","author":"I See","year":"2021","unstructured":"See, I. et al. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. JAMA 325, 2448\u20132456 (2021).","journal-title":"JAMA"},{"key":"569_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5694\/mja2.51135","volume":"215","author":"J Hocking","year":"2021","unstructured":"Hocking, J. et al. The first known case of vaccine-induced thrombotic thrombocytopenia in Australia. Med. J. Aust. 215, 19\u201320 e11 (2021).","journal-title":"Med. J. Aust."},{"key":"569_CR6","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1001\/jamaneurol.2021.3619","volume":"78","author":"M Sanchez van Kammen","year":"2021","unstructured":"Sanchez van Kammen, M. et al. Characteristics and outcomes of patients with cerebral venous sinus thrombosis in SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. JAMA Neurol. 78, 1314\u20131323 (2021).","journal-title":"JAMA Neurol."},{"key":"569_CR7","unstructured":"WHO. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria\u2122, SII COVISHIELD\u2122). https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1 (2022)."},{"key":"569_CR8","unstructured":"WHO. Interim recommendations for use of the Cansino Ad5-nCoV-S vaccine (Convidecia\u00ae) against COVID-19. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE-recommendation-Ad5-nCoV-Convidecia (2022)."},{"key":"569_CR9","unstructured":"EMA. Procedure under Article 5(3) of Regulation (EC) No 726\/2004. https:\/\/www.ema.europa.eu\/documents\/referral\/use-vaxzevria-prevent-covid-19-article-53-procedure-final-assessment-report_en.pdf (2021)."},{"key":"569_CR10","unstructured":"CDC. Population-Level Risk-Benefit Analysis. https:\/\/www.cdc.gov\/vaccines\/covid-19\/info-by-product\/janssen\/risk-benefit-analysis.html (2021)."},{"key":"569_CR11","unstructured":"WHO. Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE-recommendation-Ad26.COV2.S-2021.1 (2022)."},{"key":"569_CR12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40264-022-01187-y","volume":"45","author":"A Shoaibi","year":"2022","unstructured":"Shoaibi, A. et al. Phenotype Algorithms for the Identification and Characterization of Vaccine-Induced Thrombotic Thrombocytopenia in Real World Data: A Multinational Network Cohort Study. Drug Saf. 45, 685\u2013698 (2022).","journal-title":"Drug Saf."},{"key":"569_CR13","unstructured":"Prieto-Alhambra, D. Association between thrombosis with thrombocytopenia syndrome (TTS) or thromboembolic events, and COVID-19 vaccines. (Encepp Study number EUPAS44469). https:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=46886 (2022)."},{"key":"569_CR14","doi-asserted-by":"publisher","first-page":"e2217375","DOI":"10.1001\/jamanetworkopen.2022.17375","volume":"5","author":"J Dag Berild","year":"2022","unstructured":"Dag Berild, J. et al. Analysis of thromboembolic and thrombocytopenic events after the AZD1222, BNT162b2, and MRNA-1273 COVID-19 vaccines in 3 Nordic countries. JAMA Netw. Open 5, e2217375 (2022).","journal-title":"JAMA Netw. Open"},{"key":"569_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/jth.15572","volume":"20","author":"A Greinacher","year":"2022","unstructured":"Greinacher, A. et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT): update on diagnosis and management considering different resources. J. Thromb. Haemost. 20, 149\u2013156 (2022).","journal-title":"J. Thromb. Haemost."},{"key":"569_CR16","unstructured":"WHO. Guidance for clinical case management of thrombosis with thrombocytopenia syndrome(TTS) following vaccination to prevent coronavirus disease (COVID-19) <https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-TTS-2021.1> (2021)."},{"key":"569_CR17","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/S2214-109X(21)00545-3","volume":"10","author":"K Soboleva","year":"2022","unstructured":"Soboleva, K. et al. Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination. Lancet Glob. Health 10, e33\u2013e34 (2022).","journal-title":"Lancet Glob. Health"},{"key":"569_CR18","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood.2022016118","volume":"139","author":"S Pavord","year":"2022","unstructured":"Pavord, S. & Makris, M. Second-dose VITT: rare but real. Blood 139, 2581\u20132583 (2022).","journal-title":"Blood"},{"key":"569_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1056\/NEJMc2118507","volume":"386","author":"J Lacy","year":"2022","unstructured":"Lacy, J., Pavord, S. & Brown, K. E. VITT and second doses of Covid-19 vaccine. N. Engl. J. Med. 386, 95 (2022).","journal-title":"N. Engl. J. Med."},{"key":"569_CR20","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood.2021014214","volume":"139","author":"L Schonborn","year":"2022","unstructured":"Schonborn, L. et al. Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient. Blood 139, 1903\u20131907 (2022).","journal-title":"Blood"},{"key":"569_CR21","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1111\/jth.15423","volume":"19","author":"C Reilly-Stitt","year":"2021","unstructured":"Reilly-Stitt, C. et al. Anti-PF4 testing for vaccine-induced immune thrombocytopenia and thrombosis and heparin induced thrombocytopenia: results from a UK National External Quality Assessment Scheme exercise April 2021. J. Thromb. Haemost. 19, 2263\u20132267 (2021).","journal-title":"J. Thromb. Haemost."},{"key":"569_CR22","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1182\/blood.2021012938","volume":"138","author":"A Greinacher","year":"2021","unstructured":"Greinacher, A. et al. Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. Blood 138, 1269\u20131277 (2021).","journal-title":"Blood"},{"key":"569_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1056\/NEJMc2206601","volume":"387","author":"L Schonborn","year":"2022","unstructured":"Schonborn, L., Seck, S. E., Thiele, T., Warkentin, T. E. & Greinacher, A. SARS-CoV-2 infection in patients with a history of VITT. N. Engl. J. Med. 387, 88\u201390 (2022).","journal-title":"N. Engl. J. Med."},{"key":"569_CR24","doi-asserted-by":"publisher","unstructured":"Wang, J. J. et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT) is mediated by a stereotyped clonotypic antibody. Blood https:\/\/doi.org\/10.1182\/blood.2022016474 (2022).","DOI":"10.1182\/blood.2022016474"},{"key":"569_CR25","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1182\/blood.2021013231","volume":"138","author":"A Greinacher","year":"2021","unstructured":"Greinacher, A. et al. Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood 138, 2256\u20132268 (2021).","journal-title":"Blood"},{"key":"569_CR26","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1182\/blood-2010-08-301424","volume":"117","author":"K Krauel","year":"2011","unstructured":"Krauel, K. et al. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 117, 1370\u20131378 (2011).","journal-title":"Blood"},{"key":"569_CR27","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1309\/AJCPG0MNR5NGKNFX","volume":"134","author":"MJ Hursting","year":"2010","unstructured":"Hursting, M. J. et al. Platelet factor 4\/heparin antibodies in blood bank donors. Am. J. Clin. Pathol. 134, 774\u2013780 (2010).","journal-title":"Am. J. Clin. Pathol."},{"key":"569_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.thromres.2021.05.018","volume":"204","author":"TE Warkentin","year":"2021","unstructured":"Warkentin, T. E. & Greinacher, A. Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia. Thromb. Res. 204, 40\u201351 (2021).","journal-title":"Thromb. Res."},{"key":"569_CR29","doi-asserted-by":"publisher","unstructured":"Top, K. A. et al. Advancing the science of vaccine safety during the COVID-19 pandemic and beyond: launching an International Network of Special Immunization Services. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciac407 (2022).","DOI":"10.1093\/cid\/ciac407"},{"key":"569_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1182\/blood.2021014588","volume":"140","author":"AJ Kanack","year":"2022","unstructured":"Kanack, A. J. et al. Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT. Blood 140, 73\u201377 (2022).","journal-title":"Blood"},{"key":"569_CR31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/ajh.26488","volume":"97","author":"AJ Kanack","year":"2022","unstructured":"Kanack, A. J. et al. Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. Am. J. Hematol. 97, 519\u2013526 (2022).","journal-title":"Am. J. Hematol."},{"key":"569_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-11623-9","volume":"12","author":"TS Cohen","year":"2022","unstructured":"Cohen, T. S. et al. Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination. Sci. Rep. 12, 7961 (2022).","journal-title":"Sci. Rep."},{"key":"569_CR33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/blood.2021012217","volume":"138","author":"T Thiele","year":"2021","unstructured":"Thiele, T. et al. Frequency of positive anti-PF4\/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood 138, 299\u2013303 (2021).","journal-title":"Blood"},{"key":"569_CR34","doi-asserted-by":"publisher","first-page":"eabl8213","DOI":"10.1126\/sciadv.abl8213","volume":"7","author":"AT Baker","year":"2021","unstructured":"Baker, A. T. et al. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Sci. Adv. 7, eabl8213 (2021).","journal-title":"Sci. Adv."},{"key":"569_CR35","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1038\/s41467-022-32946-1","volume":"13","author":"HHL Leung","year":"2022","unstructured":"Leung, H. H. L. et al. NETosis and thrombosis in vaccine-induced immune thrombotic thrombocytopenia. Nat. Commun. 13, 5206 (2022).","journal-title":"Nat. Commun."},{"key":"569_CR36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-021-03744-4","volume":"596","author":"A Huynh","year":"2021","unstructured":"Huynh, A., Kelton, J. G., Arnold, D. M., Daka, M. & Nazy, I. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature 596, 565\u2013569 (2021).","journal-title":"Nature"},{"key":"569_CR37","doi-asserted-by":"publisher","unstructured":"Krutzke, L. et al. Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine. Elife 11 https:\/\/doi.org\/10.7554\/eLife.78513 (2022).","DOI":"10.7554\/eLife.78513"},{"key":"569_CR38","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3324\/haematol.2021.280154","volume":"107","author":"S Michalik","year":"2022","unstructured":"Michalik, S. et al. Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines. Haematologica 107, 947\u2013957 (2022).","journal-title":"Haematologica"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00569-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00569-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00569-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T01:03:55Z","timestamp":1667955835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00569-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["569"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00569-8","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"10 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.B. declared a research grant to institution from AstraZeneca for clinical study. A.P. reported pending\/issued patents in the area of anti-PF4 antibodies, HIT, VITT and platelet storage (assigned to Mayo Clinic, Retham Technologies, and Versiti Blood Center of Wisconsin), equity ownership in and serving as an officer of Retham Technologies, and member of the advisory board of Veralox Therapeutics. D.P.A. receives funding from the UK National Institute for Health and Care Research (NIHR) in the form of a senior research fellowship and from the Oxford NIHR Biomedical Research Centre. His research group has received funding from the European Medicines Agency and Innovative Medicines Initiative. His research group has received research grant\/s from Amgen, Chiesi-Taylor, GSK, Novartis, and UCB Biopharma. His department has also received advisory or consultancy fees from Amgen, Astellas, Astra Zeneca, Johnson and Johnson, and UCB Biopharma; and speaker fees from Amgen and UCB Biopharma. Janssen and Synapse Management Partners have supported training programmes organised by DPA\u2019s department and open for external participants organized by his department outside the submitted work. AG has received funding from the European Medicines Agency and reports consulting fees from: Aspen, Bayer Vital, Chromatec, Instrumentation Laboratory, Macopharma, Sanofi-Aventis, Roche, GTH e.V., Mylan Germany, Takeda Pharma, Falk Foundation e.V., Dilaflor, outside of this work. Also, AG has a patent Screening Methods for transfusion related acute lung injury (TRALI) with royalties paid to EP2321644, 18.05.2011. All the other authors declared no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}